Kornimate/medical-research-clean huggingface dataset:
comparison of different energy sources during tur-p

Conditions: Benign Prostatic Hypertrophy

Summary: with this study, it is aimed to compare the operative results and complication rates in transurethral resection of the prostate (tur-p) performed by resectoscopes with two different bipolar and a monopolar energy sources.

following data will be collected and evaluated prospectively for the three groups of patients who will undergo tur-p due to benign prostate hyperplasia (bph) with one of the resectoscopes using different energy sources: 1. preoperative data: age, height, weight, body-mass index, concomitant morbidities, use of any drug, history of operation, duration of lower urinary tract symptoms, history of any previous treatment taken for bph, serum level of prostate specific antigen, prostate volume, maximum and average urine flow rate, postmicturation residual urine volume, hemoglobin level 2. operative data: duration of operation, volume of resected tissue, observation of obturator reflex (if any), kind and size of the urethral catheter used 3. postoperative data: time to removal of urethral catheter, hospitalization duration, change in hemoglobin, rate of blood transfusion, any other complications

Eligibility criteria:
inclusion criteria: * having an indication due to bph * aged between 40 and 80 years old exclusion criteria: * kidney failure due to bph * any kind of coagulopathy or use of anticoagulants in the preoperative period * history of any previous open or endoscopic prostate surgery

Keywords: prostate transurethral resection bipolar monopolar
arthroscopic transosseous vs. anchored rotator cuff repair

Conditions: Shoulder Pain Chronic; Shoulder Pain; Rotator Cuff Tear; Rotator Cuff Injury

Summary: this study will compare arthroscopic transosseous versus anchored rotator cuff repairs in terms of clinical outcomes, rotator cuff integrity, and cost-effectiveness. with the collection of patient-reported outcomes the health of patients undergoing each rotator cuff repair technique will be assessed. the aims of this study will be achieved through a clinical randomized controlled trial and a cost-effectiveness analysis.

study design: after the decision to proceed with arthroscopic rotator cuff repair, patients will be asked to participate in this prospective randomized clinical trial. study procedures: before surgery: the informed consent process will be completed prior to any data collection. consent will be completed after explanation of each treatment group and the data to be collected. baseline and demographic data will be collected prior to surgery: randomization: subjects will be randomized prior to surgery into one of the two rotator cuff repair technique groups using redcap software. randomization will be stratified by gender. patient visits: patients will complete their questionnaires and testing before surgery then within 2 weeks, 3 months, 6 months, 1 year, and 2 years after the first week of surgery, patients will be given a pain diary to record all narcotic pain medications they consume during the 1st week post-op. an ultrasound will be done during their 6 month, 1 year, and 2 year follow up.

Eligibility criteria:
inclusion criteria: * adults age 18-75 years old * full thickness rotator cuff tears of any size (documented by mri or ultrasound) * patients planning surgical repair with dr. uma srikumaran (pi of this study) at johns hopkins shoulder service (columbia, odenton clinic sites; howard county general hospital/bayview/johns hopkins hospital operative sites) exclusion criteria: * patients with partial tears, massive rotator cuff tears that are irreparable, isolated subscapularis tears, and associated pathology (advanced degenerative changes) * patients undergoing revision rotator cuff tears will be excluded.
dry eye management with 3% diquafosol before and after cataract surgery

Conditions: Dry Eye

Summary: the objective of this study is to evaluate the efficacy of diquafosol 3% in the management of dry eyes before and after cataract surgery. patients with pre-existing dry eyes and planned for cataract surgery will be started on diquafosol eyedrops prior to surgery and treatment will be continued after cataract surgery. eligible patients will undergo evaluation of dry eye at baseline and subsequently started on treatment with diquafosol for the duration of 4 weeks before surgery. further evaluations will be conducted on the day of surgery and at designated time points during and up to 12 weeks after surgery.

title: dry eye management with 3% diquafosol before and after cataract surgery setting: lec eye centre, ipoh, malaysia background: dry eye disease and cataract are two conditions which have been known to increase in incidence with age. dry eye disease can also be further exacerbated by cataract surgery. diquafosol (diquas) is a p2y2 receptor agonist which improves mucin and tear secretion and is a 'first in class' therapeutic option which has been shown repeatedly to be efficacious in dry eye management. objective: to evaluate the efficacy of diquafosol for dry eye management in patients with pre-existing dry eye disease before and after cataract surgery design: observational case series in a private ophthalmic health facility study plan: eligible patients will have treatment with diquas for 4 weeks prior to undergoing cataract surgery. preoperative clinical evaluation will include documentation of severity of signs and symptoms of dry eye and this will be carried out at baseline, immediately before surgery and subsequently at week 4 and week 12.

Eligibility criteria:
inclusion criteria: 1. eyes with pre-existing dry eye and visually significant cataract planned for phacoemulsification 2. patients aged18years or older and in good general health 3. mild to moderate dry eye; non-visually significant ocular surface disease (nvs-osd) defined as corneal fluorescein staining (cfs) score of \<3 on the oxford scale 4. tear break-up time (tbut) \<10 seconds exclusion criteria: 1. eyes with complications after cataract surgery which require a prolonged course of topical medication 2. eyes with history of contact lens wear in the previous 3 months 3. eyes with history of regular use of topical eye drops(except artificial tears) in the previous 6 months 4. treatment history of dry eye beyond artificial tears 5. eyes with significant ocular surface disease (defined as cfs score of ≥3 on the oxford scale) 6. eyes with lacrimal or eyelid disease or ocular surface infections 7. any ocular surgery within the prior 6 months 8. using medications that could affect the dry eye condition (eg, antihistamines, antidepressants, decongestants, anticholinergic drugs or hormone treatment) 9. allergies to diquafosol
genetic determinant of blood pressure sensitivity to salt intake

Conditions: Hypertension

Summary: nedd4.2 is a regulator of enac, a transporter of sodium involved in the regulation of salt retention by the kidney. the study address the consequence of a frequent genetic variation leading expected to impact the function of nedd4 and in turn, the ability of kidneys to excrete salt intake. our hypothesis is that the genetic variants of nedd4.2 could constitute a genetic predisposition to (or protection against) salt-sensitive hypertension.

subjects were submitted one week to a low sodium-high potassium diet, and then switch to a high sodium,-low potassium diet for two weeks. the last week, subject were taken a 20 mg daily dose of amiloride, a potassium sparing diuretic.

Eligibility criteria:
inclusion criteria: * healthy volunteers * between 18 and 35 years odl * bmi between 18 and 28 kg per m2 * non smokers * no active disease * no alcool or drug abuse

Keywords: nedd4-2 blood pressure polymorphism salt intake between 18 and 35 years old bmi between 18 and 28 kg per m2 no active disease no alcool or drug abuse or smoke
study of recombinant factor ix product, ib1001, in subjects with hemophilia b

Conditions: Hemophilia B

Summary: primary objective: to evaluate the safety (acute effects associated with infusions, and inhibitor development), pharmacokinetics (pk), and efficacy with respect to breakthrough bleeding during prophylaxis and with respect to control of hemorrhaging in both the prophylaxis and on demand groups of ib1001 in subjects with hemophilia b. key secondary objectives: to evaluate the ability of ib1001 to provide coverage against bleeding under surgical circumstances; to evaluate the long-term safety and efficacy of ib1001


Eligibility criteria:
inclusion criteria: 1. patient must be willing to give written institutional review board (irb)/independent ethics committee (iec)-approved informed consent, make the required study visits, and follow instructions while enrolled in the study 2. severe (factor ix activity ≤2 u/dl) hemophilia b subjects on demand therapy with a minimum of 3 bleeding episodes over the preceding 6 months or 6 bleeding episodes over the preceding 12 months; subjects on prophylaxis with a bleeding pattern as above demonstrated prior to starting prophylaxis 3. immunocompetent (cd4 count \>400/mm3) and not receiving immune modulating or chemotherapeutic agents 4. previously treated patients with a minimum of 150 exposure days to a factor ix preparation 5. platelet count at least 150,000/mm3 6. liver function: alanine transaminase \[alt\] and aspartate transaminase \[ast\] ≤2 times the upper limit of the normal range 7. total bilirubin ≤1.5 times the upper limit of the normal range 8. renal function: serum creatinine ≤1.25 times the upper limit of the normal range 9. willingness to participate in the trial for up to 12-15 months 10. european union (eu), israel, and canada: age of at least 12 years and body weight of ≥40 kilograms to participate in any pk study or the surgical sub-study \[the surgical sub-study does not apply to the uk\]; age of at least 12 years for the prophylaxis and on demand components of the treatment phase and continuation study united states (us): age of at least 12 years and body weight of ≥40 kilograms to participate in any pk study or the surgical sub-study; age of at least 5 years for the prophylaxis and on demand components of the treatment phase and continuation study 11. hemoglobin ≥7 g/dl at the time of the blood draw exclusion criteria: 1. history of factor ix inhibitor ≥0.6 bethesda units (bu) 2. existence of another coagulation disorder 3. evidence of thrombotic disease, fibrinolysis, or disseminated intravascular coagulation (dic) 4. use of an investigational drug within 30 days prior to study entry 5. on medications that could impact hemostasis, such as aspirin 6. history of poor compliance, a serious medical or social condition, or any other circumstance that, in the opinion of the investigator, would interfere with participation or compliance with the study protocol 7. history of adverse reaction to either plasma-derived factor ix or recombinant factor ix that interfered with the subject's ability to treat bleeding episodes with a factor ix product
incretin-based therapy in early diagnosed type 1 diabetes

Conditions: Type 1 Diabetes

Summary: the main objective of the trial is to study whether daily treatment with liraglutide improves insulin secretion and reduces the requirement of exogenous insulin, and whether liraglutide treatment is tolerable and safe in subjects aged 10-30 years, having an early diagnosis of type 1 diabetes (no symptoms, diagnosis in ogtt), and treated with insulin.


Eligibility criteria:
inclusion criteria: * 10-30 years of age * early diagnosis type 1 diabetes (no symptoms, diagnosis in ogtt) * not pregnant. exclusion criteria: * allergic to liraglutide or other ingredients of victoza® * diabetic ketoacidosis * previous treatment in the last three months with any antidiabetic medication other than insulin * impaired liver or kidney function or on dialysis * severe heart failure * severe stomach or gut problem resulting in gastroparesis, or inflammatory bowel disease * past or current history of pancreatitis * serum calcitonin value above normal (\>50 ng/l or ≥3.4pmol/l) * presence of any chronic metabolic, hematologic or malignant disease * obesity bmi ≥30 * pregnant females and females of childbearing potential who are not using adequate contraceptive methods. * breast-feeding

Keywords: diabetes type 1 diabetes, insulin-dependent liraglutide glp-1 analogue early diagnosis
randomized, double blind, placebo control trial to evaluate the efficacy of astragalus membranaceus in the patients after stroke with fatigue

Conditions: Fatigue; Stroke

Summary: the high levels of fatigue in stroke patients without neurological impairment suggest it has a central origin rather than being the result of increased physical effort required after stroke（winward et al., 2009）. fatigue is different from post-stroke depression and the more serious stroke patients are more prone to fatigue（windward et al., 2009）. fatigue is one of the symptoms of qi deficiency,and astragalus membranaceus is the most effective of all traditional chinese medicine and can tonifying middle and tonify the original qi. therefore, the aim of this study was to investigate the efficacy of astragalus membranaceus on post-stroke fatigue.


Eligibility criteria:
inclusion criteria: 1. gender: male or female. 2. age: between 40 and 80 years old. 3. three months after stroke. 4. hemorrhagic stroke or ischemic stroke. 5. fatigue score from screen process ≧4. 6. subject with comprehension or communication. 7. volunteer signs the agreement to participate the study after whole study purpose and procedures description in detail. exclusion criteria: 1. people from mental illness can not to participate the evaluation. 2. major diseases such as cancer、chronic pulmonary obstructive disease(copd)、 heart failure、myocardial infraction、chronic renal failure or liver cirrhosis. 3. pregnant woman. 4. breast-feeding woman.

Keywords: after stroke with fatigue
safety and tolerability study of cova322 in patients with stable chronic moderate-to-severe plaque psoriasis

Conditions: Plaque Psoriasis

Summary: this study is a randomised, double-blind, placebo-controlled, sequential, ascending single-dose, parallel group study to evaluate safety, tolerability, biological activity, and systemic exposure of cova322 (tumor necrosis factor alpha (tnf-α) / interleukin 17 a (il-17a) antibody fusion protein) in patients with stable chronic moderate-to-severe plaque psoriasis. patients will receive ascending single-doses of cova322 or placebo as a constant-rate i.v. infusion, followed by 12 weeks of evaluation.


Eligibility criteria:
inclusion criteria: * male or female subjects of any ethnic origin; women must be of non-childbearing potential * aged between 18 to 65 yrs inclusive * body weight of ≥ 40 kg and body mass index between 19 - 32 kg/m2 inclusive * established diagnosis of moderate to severe plaque psoriasis for at least 6 months prior to screening. the patients must meet all of the following criteria: * psoriasis involving ≥ 10% of body surface area * requirement of phototherapy or systemic therapy * psoriasis area and severity index (pasi) score of ≥ 10 * physician"s global assessment (pga) score of ≥ 3 * stable disease exclusion criteria: * history of clinically relevant allergies or idiosyncrasies to cova322 * any history of clinically significant drug hypersensitivity following any therapy with a therapeutical biologic, or asthma, urticaria, or other allergic diathesis * clinically significant flare of psoriasis during the 12 weeks before randomization * current evidence of non-plaque forms of psoriasis * currently evidence of drug-induced psoriasis * evidence of any serious systemic or local infection within 3 months before screening * evidence of subclinical/latent tuberculosis infection * history or any signs of lymphoproliferative disease, or a known malignancy or a history of malignancy within the previous 5 years * history or current evidence of autoimmune diseases other than psoriasis * women of child-bearing potential * recent previous exposure to systemic psoriasis treatments, including anti-tnf-α therapies, immunosuppressive agents such as cyclosporine, mycophenolate, or tacrolimus, and other medications affecting the immune function * alanine aminotransferase (alt) or aspartate aminotransferase (ast) level ≥ 2.5 times the upper limit of normal (uln) at screening * serum creatinine level ≥ 1.5 times the uln at screening * positive results in any of the virology tests for hiv-ab, hepatitis c-virus antibody (hcv-ab) and hepatitis b-virus surface antigen (hbsag) or hepatitis b core antibody (hbc-ab)
a trial of shr-1210 (an anti-pd-1 antibody) in combination with apatinib in patients with advanced tnbc

Conditions: Breast Cancer

Summary: this is a phase ii, open-labeled, randomised, parallel, non-comparative, two-arms, investigator-initiated clinical trial of shr-1210 (anti-pd-1 antibody) in combination with apatinib (vegfr2 inhibitor) in subjects with advanced triple negative breast cancer. subjects with advanced triple negative breast cancer will be recruited. patients will be randomised to two treatment arms of this study. one arm is shr-1210 combination with apatinib daily dosing, and the other arm is shr-1210 combination with apatinib intermittent dosing; each arm will enrolle10-29 subjects (simons two stage design). this study aims to evaluate the efficacy and safety of shr-1210 combination with apatinib in the treatment of advanced tnbc.


Eligibility criteria:
inclusion criteria: * the patients signed the written informed consent * women aged 18-70. * the pathologic diagnosis of recurrent metastatic triple negative breast cancer ［er-negative(ihc\<1%), pr-negative(ihc\<1%), her2-negative（ihc-/+ or ihc++ and fish/cish-）］. * at least one measuring lesion that conforms to recist v1.1 standard. * the number of chemotherapy lines in the metastatic phase was \<3 line. * eastern cooperative oncology group (ecog) performance status of ≤ 1. * have a life expectancy of at least 12 weeks. * female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 3 months after the last dose of study treatment. * the patients can swallow pills. * the results of patients' blood tests are as follows: • hb≥90g/l; • plt≥90e+9/l; • neutrophils≥1.5e+9/l; • alt and ast ≤ triple of normal upper limit; • tbil ≤ 1.5 times of normal upper limit; • creatinine ≤ 1.5 times of normal upper limit. exclusion criteria: * the subjects had any history of autoimmune disease or any use of systemic glucocorticoid or immunosuppressive medications. * subjects with severe allergic reactions to other monoclonal antibodies. * the subjects had a central nervous system metastases with clinical symptoms. * history of hypertension and antihypertensive medications are not well controlled. * a heart condition or disease that is not well controlled. * subjects had active infections or recent treatment with a systemic immunostimulatory agent (received within the previous 4 weeks). * other clinical trials of drugs were used in the first four weeks of the first medication. * subjects with treatment history of anti-angiogenesis drugs or check-point inhibitors.
health-related quality of life and late effects among survivors of cancer in adolescence and young adulthood: the survaya study

Conditions: Quality of Life; Late Effect; Survivorship; Lifestyle; Cancer

Summary: rationale: adolescent and young adult (aya) cancer survivors, diagnosed between 18-39 years, much more than children, suffer from delay in diagnosis, lack of centralization of care, age-adjusted expertise and follow-up care. the distribution of tumor types, biology, risk factors, developmental challenges and treatment regimens are different in ayas compared to children. therefore findings derived from childhood cancer survivors cannot be extrapolated to ayas. likewise, several large tumor-specific cohort studies exist that do not specifically address unique aya age-specific issues. globally, so far, the identification of aya patient subgroups that might be more susceptible to poor health outcomes has not been systematically addressed. the role of sociodemographic and treatment-associated risks, external exposures (e.g. lifestyle) and host factors (e.g. genetic); or combinations of influences for impaired (age-specific) health outcomes, remains largely unknown. understanding who is at risk and why, will support the development of evidence-based aya prevention, treatment and supportive care programs and guidelines. objective: to examine the prevalence, risk factors and mechanisms of impaired health outcomes (health-related quality of life and late effects) among a population-based sample of aya cancer survivors. study design: retrospective, population-based, observational cohort study. study population: aya cancer survivors, diagnosed at age 18-39 years between 1999-2015, identified from the netherlands cancer registry (ncr), and alive 5-20 year after diagnosis main study parameters/endpoints: health-related quality of life; late effects


Eligibility criteria:
inclusion criteria: * pathological confirmed cancer diagnosis; * age 18 - 39 years at time of first cancer diagnosis; * provide written informed consent. * treated in an academic hospital or netherlands cancer institute
e-biomatrix postmarket surveillance registry

Conditions: Coronary Artery Disease

Summary: the purpose of the e-biomatrix pms registry is to capture clinical data of the biomatrix (biolimus a9-eluting) stent system in relation to safety and effectiveness.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. patients that need a treatment with a biomatrix™ drug-eluting stent 3. presence of one or more coronary artery stenoses in a native coronary artery or a saphenous bypass graft from 2.25 to 4.0 mm in diameter that can be covered with one or multiple stents 4. no limitation on the number of treated lesions, and vessels, and lesion length exclusion criteria: 1. inability to provide informed consent 2. patients needing additional stent not of the biomatrix™ type 3. patients receiving next to the biomatrix™ stent also other coronary vascular interventions, for example dilation.
a study to compare the effectiveness of adductor canal pain catheters following total knee arthroplasty

Conditions: Osteoarthritis, Knee

Summary: the purpose of this research is to study how well the adductor canal pain catheters works after a total knee arthroplasty or replacement of the knee joint. the catheter works by using either an intermittent bolus injection to provide a large dose of medication or continuous infusion of pain medicine, ropivacaine 0.2%, compared to a single-shot adductor canal block.


Eligibility criteria:
inclusion criteria: * age ≥ 18 and ≤ 90 years. * willing to participate in the study and competent to provide informed consent. * willing to comply with protocol procedures. * has an underlying diagnosis of osteoarthritis indicated for a total knee arthroplasty. exclusion criteria: * the patient must not have taken any narcotic medications (schedule ii) during the 3 months leading up to the surgery. * the patient must not be allergic or intolerant to a medication used in the multimodal pain pathway. * revision knee arthroplasty. * uncontrolled diabetes with a1c \> 8.0%.